In vitro antibacterial activity of tigecycline against clinical isolates of Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococci (LRE) by time-kill assay

Introduction: Enterococci have become the third major leading cause of nosocomial bacteraemia, an infection which is significantly associated with the risk of developing infective endocarditis. Linezolid provides high rates of clinical cure and microbiologic success in complicated infections due to...

Full description

Bibliographic Details
Main Authors: Gustavo Enck Sambrano, Thiago Galvão da Silva Paim, Lucas Toniolo da Silva, Pedro Alves d'Azevedo
Format: Article
Language:English
Published: Hospital de Clinicas de Porto Alegre ; Universidade Federal do Rio Grande do Sul (UFRGS) 2014-08-01
Series:Clinical and Biomedical Research
Subjects:
Online Access:http://seer.ufrgs.br/index.php/hcpa/article/view/48369
id doaj-0fec0216a696406eb487881039d90de4
record_format Article
spelling doaj-0fec0216a696406eb487881039d90de42020-11-25T02:26:37ZengHospital de Clinicas de Porto Alegre ; Universidade Federal do Rio Grande do Sul (UFRGS)Clinical and Biomedical Research0101-55752357-97302014-08-0134325371In vitro antibacterial activity of tigecycline against clinical isolates of Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococci (LRE) by time-kill assayGustavo Enck Sambrano0Thiago Galvão da Silva Paim1Lucas Toniolo da Silva2Pedro Alves d'Azevedo3UFCSPAUFCSPAUFCSPAUFCSPAIntroduction: Enterococci have become the third major leading cause of nosocomial bacteraemia, an infection which is significantly associated with the risk of developing infective endocarditis. Linezolid provides high rates of clinical cure and microbiologic success in complicated infections due to Enterococcus spp. However, several instances of emergence of resistance during linezolid treatment have been reported. The aim of this study was evaluate the activity of tigecycline against Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococcus faecalis (LRE) by the time-kill assay. Methods: Five isolates of LRE and two isolates of LIE were used in this study. MICs were determined by broth dilution following the CLSI (2014) guidelines. Time-kill assay was employed to access the in vitro response profile of tigecycline. Results: All seven of the isolates presented MIC of 0.125μg/mL. Tigecycline activity was individually evaluated and in three of the five isolates of LRE it presented bactericidal. Against the other isolates, tigecycline showed bacteriostatic activity. The tigecycline activity was measured according to CLSI criteria. Conclusions: Tigecycline presented both bacteriostatic and bactericidal activity against tested isolates, result not yet described in previous studies. Time and concentrations above MIC were key factors to achieving bactericidal effect. MIC and the tested concentration below it resulted in bacteriostatical effect to enterococci, corroborating previous data.http://seer.ufrgs.br/index.php/hcpa/article/view/48369EnterococcusAnti-Infective AgentsBacterial Growth
collection DOAJ
language English
format Article
sources DOAJ
author Gustavo Enck Sambrano
Thiago Galvão da Silva Paim
Lucas Toniolo da Silva
Pedro Alves d'Azevedo
spellingShingle Gustavo Enck Sambrano
Thiago Galvão da Silva Paim
Lucas Toniolo da Silva
Pedro Alves d'Azevedo
In vitro antibacterial activity of tigecycline against clinical isolates of Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococci (LRE) by time-kill assay
Clinical and Biomedical Research
Enterococcus
Anti-Infective Agents
Bacterial Growth
author_facet Gustavo Enck Sambrano
Thiago Galvão da Silva Paim
Lucas Toniolo da Silva
Pedro Alves d'Azevedo
author_sort Gustavo Enck Sambrano
title In vitro antibacterial activity of tigecycline against clinical isolates of Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococci (LRE) by time-kill assay
title_short In vitro antibacterial activity of tigecycline against clinical isolates of Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococci (LRE) by time-kill assay
title_full In vitro antibacterial activity of tigecycline against clinical isolates of Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococci (LRE) by time-kill assay
title_fullStr In vitro antibacterial activity of tigecycline against clinical isolates of Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococci (LRE) by time-kill assay
title_full_unstemmed In vitro antibacterial activity of tigecycline against clinical isolates of Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococci (LRE) by time-kill assay
title_sort in vitro antibacterial activity of tigecycline against clinical isolates of linezolid-intermediate (lie) and linezolid-resistant enterococci (lre) by time-kill assay
publisher Hospital de Clinicas de Porto Alegre ; Universidade Federal do Rio Grande do Sul (UFRGS)
series Clinical and Biomedical Research
issn 0101-5575
2357-9730
publishDate 2014-08-01
description Introduction: Enterococci have become the third major leading cause of nosocomial bacteraemia, an infection which is significantly associated with the risk of developing infective endocarditis. Linezolid provides high rates of clinical cure and microbiologic success in complicated infections due to Enterococcus spp. However, several instances of emergence of resistance during linezolid treatment have been reported. The aim of this study was evaluate the activity of tigecycline against Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococcus faecalis (LRE) by the time-kill assay. Methods: Five isolates of LRE and two isolates of LIE were used in this study. MICs were determined by broth dilution following the CLSI (2014) guidelines. Time-kill assay was employed to access the in vitro response profile of tigecycline. Results: All seven of the isolates presented MIC of 0.125μg/mL. Tigecycline activity was individually evaluated and in three of the five isolates of LRE it presented bactericidal. Against the other isolates, tigecycline showed bacteriostatic activity. The tigecycline activity was measured according to CLSI criteria. Conclusions: Tigecycline presented both bacteriostatic and bactericidal activity against tested isolates, result not yet described in previous studies. Time and concentrations above MIC were key factors to achieving bactericidal effect. MIC and the tested concentration below it resulted in bacteriostatical effect to enterococci, corroborating previous data.
topic Enterococcus
Anti-Infective Agents
Bacterial Growth
url http://seer.ufrgs.br/index.php/hcpa/article/view/48369
work_keys_str_mv AT gustavoencksambrano invitroantibacterialactivityoftigecyclineagainstclinicalisolatesoflinezolidintermediatelieandlinezolidresistantenterococcilrebytimekillassay
AT thiagogalvaodasilvapaim invitroantibacterialactivityoftigecyclineagainstclinicalisolatesoflinezolidintermediatelieandlinezolidresistantenterococcilrebytimekillassay
AT lucastoniolodasilva invitroantibacterialactivityoftigecyclineagainstclinicalisolatesoflinezolidintermediatelieandlinezolidresistantenterococcilrebytimekillassay
AT pedroalvesdazevedo invitroantibacterialactivityoftigecyclineagainstclinicalisolatesoflinezolidintermediatelieandlinezolidresistantenterococcilrebytimekillassay
_version_ 1724845863003488256